-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer – August 2022
The urgent need for effective preventive vaccine and efficacious therapeutics for COVID-19 has given rise to an unprecedented pace of R&D by the biopharmaceutical industry, coupled with substantial investment by governments, non-profit agencies, and other stakeholders. There are currently more than 1,800Â assets in development for COVID-19, the majority of which are very early-stage or have little data available. The Coronavirus Disease 2019 (COVID-19) clinical and commercial analyzer report looks at the data from clinical trials for vaccines and therapeutics either...
-
Product Insights
Leiomyosarcoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. The Leiomyosarcoma - drugs in development research report provides a comprehensive overview on the...
-
Sector Analysis
COVID-19: Contract Pharmaceutical Development and Manufacturing Relationships
This report examines contract manufacturing agreements for vaccines and therapies targeting COVID-19. It reports that there are more than 1,000 vaccines and therapies in development for COVID-19, and 36 vaccines and therapies approved (or granted emergency use authorization) for COVID-19 (as of report publication). At the beginning of the pandemic, slightly more than half of these agreements were for vaccines; this proportion has risen and continues to rise, as several vaccines have proven their safety and efficacy, received approval, and...
-
Sector Analysis
OpportunityAnalyzer: Huntington’s Disease – Opportunity Analysis and Forecast to 2024
HD is a rare, autosomal-dominant, neurodegenerative disorder, characterized by impaired motor control, cognitive dysfunction, behavioral changes, and mood disorders. Approved treatments for HD across the 7MM are extremely limited, consisting of only two symptomatic treatments, tetrabenazine and tiapride, which are both approved for the treatment of HD-associated chorea. Other treatment options contributing to the HD market are off-label symptomatic drugs, many of which are widely genericized throughout the 7MM. Four late-stage pipeline drugs, two symptomatic treatments (SD-809 and pridopidine) and...